Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. In this series, we track Inflectra’s awareness and uptake since launch, to understand how its entry will shape the evolving U.S. immune biologics market. Along with awareness, familiarity, and perceptions of biosimilars in general, and Inflectra specifically, the research also explores the drivers and barriers behind uptake of biosimilars/Inflectra. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking comparisons against other available biosimilars, to better understand the dynamics of the U.S. biosimilars market.
- Are U.S. physicians aware of Inflectra and its clinical development?
- What are the drivers to prescribing Inflectra? What is the current level of Inflectra use, and how is that changing over time?
- Has experience with Inflectra changed physicians’ opinions on biosimilars?
- Have physicians experienced pressures to prescribe Inflectra to patients?
- What promotional messages are sales representatives employing for Inflectra and Remicade?
- How does initial formulary placement of Inflectra compare with other TNF-alpha inhibitors, and does this change over time?
- Markets covered: United States
- Primary research: Survey of 91 U.S. rheumatologists, gastroenterologists, and dermatologists
Key Companies Mentioned:
- Johnson & Johnson/Janssen
Key Drugs Mentioned:
- Remicade (infliximab)
- Inflectra (infliximab-dyyb)
- Enbrel (etanercept)
- Humira (adalimumab)